Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innoviva Inc (NQ: INVA )

19.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 19.88
Bid (Size) 17.01 (1)
Ask (Size) 20.19 (150)
Prev. Close 19.88
Today's Range 19.88 - 19.88
52wk Range 12.22 - 20.19
Shares Outstanding 65,504,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024
INVA stock results show that Innoviva missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+21.44%
+21.44%
1 Month
-0.80%
-0.80%
3 Month
+15.92%
+15.92%
6 Month
+37.39%
+37.39%
1 Year
+48.25%
+48.25%

More News

Read More
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
Via InvestorPlace
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
Via InvestorPlace
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Via Benzinga
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
3 Under-$20 Stocks That Could Make You a Fortune
Via InvestorPlace
INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in the BofA Securities Health Care Conference
From Innoviva, Inc.
Via Business Wire
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
From Innoviva Specialty Therapeutics
Via Business Wire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
Via InvestorPlace
Chart Of The Day: Innoviva - Individual Investor Favorite
Via Talk Markets
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
From Innoviva Specialty Therapeutics
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Innoviva to Participate in the Cantor Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
From Innoviva, Inc.
Via Business Wire
Innoviva Appoints Stephen Basso as Chief Financial Officer
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.